Axillary Microbiota is Associated with Cognitive Impairment in Parkinson’s Disease Patients

Autor: N. H. Yilmaz, Z. Yildiz, Lutfu Hanoglu, T. Kahraman Demir, M. Arikan, A. Sen, Süleyman Yildirim
Přispěvatelé: Sağlık Hizmetleri Meslek Yüksekokulu
Rok vydání: 2021
Předmět:
DOI: 10.1101/2021.10.11.21264832
Popis: IntroductionCognitive impairment (CI) is among the most common non-motor symptoms of Parkinson’s disease (PD) with substantially negative impact on patient management and outcome. The development and progression of CI exhibits high interindividual variability which requires better diagnostic and monitoring strategies. PD patients often display sweating disorders resulting from autonomic dysfunction which has been associated with CI. As the axillary microbiota is known to change with humidity level and sweat composition, we hypothesized that axillary microbiota of PD patients shifts in association with CI progression thus can be used as proxy for classification of CI stages in PD.MethodsWe compared the axillary microbiota compositions of 103 PD patients (55 PD patients with dementia (PDD) and 48 PD patients with mild cognitive impairment (PD-MCI)) and 26 cognitively normal healthy controls (HC).ResultsWe found that axillary microbiota profiles differentiate HC, PD-MCI and PDD groups based on differential ranking analysis and detected an increasing trend in the log ratio of Corynebacterium to Anaerococcus in progression from HC to PDD. In addition, phylogenetic factorization revealed that the depletion of Anaerococcus, Peptoniphilus and W5053 genera is associated with PD-MCI and PDD. Moreover, functional predictions suggested significant increase of myo-inositol degradation, ergothioneine biosynthesis, propionate biosynthesis, menaquinone biosynthesis, and the proportion of aerobic bacteria and biofilm formation capacity in parallel to CI.ConclusionOur results suggest that alterations in axillary microbiota are associated with CI in PD. Thus, axillary microbiota holds potential to be exploited as a non-invasive biomarker in the development of novel strategies.
Databáze: OpenAIRE